Solid Biosciences Inc. (NASDAQ:SLDB) develops therapies for neuromuscular and cardiac diseases in the US. In addition, the ...
Doug Ingram of Sarepta Therapeutics is my pick for the Worst Biopharma CEO of 2025. He was an easy selection, but unlike some ...
A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...
A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.
Average Upside Potential as of December 10: 104.08% ...
The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...
Investor attention has returned to Sarepta Therapeutics amid reports of the biotech firm's vigorous legal strategy to protect ...
Scotland’s NHS can now offer givinostat to ambulant children with Duchenne muscular dystrophy, marking a step forward in care ...
Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results